er Hos patienter, som blev revaskulariseret med fibrinolytika, reducerede fondaparinux incidensen af død/ re- MI signifikant efter 30 dage fra 13, 6% for kontrolgruppen til 10, 9% (hazard rate 0, 79; 95% CI 0, 68- 0, 93; p= 0, 003).
Among patients initially not reperfused, the incidence of death/ re-MI at Day 30 was significantly reduced from 15% for the control group to 12.1% for the fondaparinux group (hazard ratio 0.79, 95% CI, 0.65; 0.97, p = 0.023).